Untreated central nervous system (CNS) metastases or CNS metastases that have progressed
Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases;
Symptomatic and/or untreated central nervous system metastases
Symptomatic and/or untreated CNS metastases
Symptomatic or untreated central nervous system (CNS) metastases
Known untreated or active central nervous system (CNS) metastases (progressing or requiring anticonvulsant medications or corticosteroids for symptomatic control); a CT or MRI scan of the brain will be performed at screening if required by the local health authority
Presence of symptomatic or untreated central nervous system (CNS) metastases
Symptomatic and/or untreated central nervous system metastases
Untreated, symptomatic Central nervous system (CNS) metastases
Primary central nervous system (CNS) malignancy, untreated CNS metastases, or active CNS metastases (progressing or requiring corticosteroids for symptomatic control)
Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.
Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
Current untreated brain metastasi(e)s; if treated history of central nervous system (CNS) metastases, should have completed radiation or surgery at least  weeks prior and off systemic corticosteroids
Patients with symptomatic, untreated central nervous system (CNS) metastases are not eligible
Symptomatic untreated metastases in the central nervous system
Symptomatic, untreated, or uncontrolled central nervous system (CNS) metastases or seizure disorder; NOTE: patients with treated CNS metastases without evidence of progression and without uncontrolled symptoms or need for steroids may enroll
Have or do not have active (untreated or progressing) CNS metastases.
Central nervous system metastases that are untreated or symptomatic, or require radiation, surgery, or continued steroid therapy to control symptoms within  days of study entry.
Subjects with symptomatic, untreated metastases to the central nervous system (CNS) at the time of screening.
Untreated brain or central nervous system (CNS) metastases or brain/CNS metastases that have progressed.
Untreated brain or central nervous system (CNS) metastases or brain or CNS metastases that have progressed as per protocol-defined criteria.
Symptomatic and/or untreated central nervous system (CNS) metastases; patients with asymptomatic previously treated CNS metastases are eligible provided they have been clinically stable for at least  weeks
Symptomatic and/or untreated or actively progressing central nervous system (CNS) metastases or leptomeningeal disease. Patients with a history of treated CNS metastases are eligible, provided that all of the following criteria are met:
Symptomatic or untreated central nervous system (CNS) metastases
Untreated brain metastases or neurologically unstable central nervous system (CNS) metastases
Subject has symptomatic/untreated CNS disease
Untreated central nervous system (CNS) metastases or symptomatic CNS metastases requiring escalating doses of corticosteroids
Untreated brain or central nervous system (CNS) metastases or brain/CNS metastases that have progressed
Subjects with untreated CNS metastases are excluded.
Untreated central nervous system (CNS) metastases or CNS metastases that have progressed
Untreated or symptomatic central nervous system (CNS) metastases
known central nervous system (CNS) metastases that are untreated, symptomatic, or require steroids to control symptoms
Known symptomatic central nervous system (CNS) metastases. Participants with a history of treated or untreated asymptomatic CNS metastases may be eligible.
Subject has symptomatic and untreated central nervous system (CNS) disease
Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
Symptomatic, untreated CNS metastases
Patients with untreated or symptomatic central nervous system (CNS) metastases
Untreated or symptomatic central nervous system metastases.
Known primary central nervous system (CNS) malignancy, active or untreated CNS metastases, symptomatic CNS metastases, and/or leptomeningeal disease
Symptomatic and/or untreated central nervous system metastases
Presence of symptomatic or untreated central nervous system (CNS) metastases, or CNS metastases that require doses of corticosteroids within the prior  weeks to Study Day
Known primary central nervous system (CNS) malignancy or symptomatic or untreated CNS metastases
Untreated or symptomatic central nervous system (CNS) metastases
Untreated central nervous system (CNS) metastasis that are >  cm or symptomatic are not allowed; (patients with CNS metastases >  cm or symptomatic that have been treated and demonstrated to be radiologically and clinically stable for at least  weeks are allowed)
Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
Evidence of untreated CNS metastases
Any untreated CNS metastases
Symptomatic or untreated central nervous system (CNS) metastases requiring concurrent treatment
Untreated or symptomatic central nervous system (CNS) metastases. Patients with asymptomatic CNS metastases are eligible provided they have been clinically stable for at least  weeks.
Untreated central nervous system (CNS) metastases or CNS metastases that have progressed after completion of radiotherapy.
Active, untreated CNS metastases.
Participants with untreated CNS metastases are excluded
Known primary central nervous system (CNS) malignancy or symptomatic or untreated CNS metastases. Treated and stable CNS metastases are allowed.
Patients with untreated central nervous system (CNS) metastases; patients with treated CNS metastases who are off steroids are eligible
Untreated or active central nervous system (CNS) metastases. Participants with a history of treated CNS metastases may be eligible
Untreated central nervous system (CNS) metastases or active (progressing or requiring corticosteroids for symptomatic control) CNS metastases
Symptomatic and/or untreated central nervous system metastases
Active, untreated CNS metastases
Has untreated or uncontrolled central nervous system (CNS) metastases, including patients who require glucocorticoid therapy for CNS metastases
Untreated/active central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control)
Primary central nervous system (CNS) malignancy, untreated CNS metastases, or active CNS metastases (progressing or requiring corticosteroids for symptomatic control)
Primary central nervous system (CNS) malignancy or untreated/active CNS metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control)
Central nervous system (CNS) disease that is untreated, symptomatic, or requires therapy to control symptoms.
Symptomatic, untreated or unstable central nervous system or leptomeningeal metastases